Your browser is no longer supported. Please, upgrade your browser.
Eucrates Biomedical Acquisition Corp.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week0.50%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float9.84M Perf Month1.51%
Income- PEG- EPS next Q- Inst Own37.60% Short Float0.01% Perf Quarter-9.01%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.18 Perf Half Y0.80%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range9.90 - 11.17 Perf YTD-5.25%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-9.58% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low2.02% ATR0.10
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)50.75 Volatility0.19% 0.60%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close10.10
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.33K Price10.10
Recom- SMA200.37% SMA500.33% SMA200-2.04% Volume0 Change0.00%
Jun-01-21 08:00AM  
May-11-21 03:51AM  
Dec-14-20 05:22PM  
Oct-27-20 04:17PM  
Oct-23-20 09:15AM  
Eucrates Biomedical Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.